Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Richard Conway RichardPAConway
3 years 1 month ago
Wipfler et al. 1 in 17 individuals prescibed MTX experienced an unexpected barrier in Post-Roe era. @RheumNow #ACR22 Abstr#L09 https://t.co/a8RDZF3JKy https://t.co/cyxJj2adgw
Richard Conway RichardPAConway
3 years 1 month ago
Maughan et al inc the late, great, Justin Mason. Treatment cessation in TAK. Feasible in some patients. Initial treatment response, age and Numanotype V arterial involvement predictors. @RheumNow #ACR22 Abstr#L017 https://t.co/5t00prCtFT https://t.co/GGUUNQqyoL
Richard Conway RichardPAConway
3 years 1 month ago
Terrier @TerrierBen et al. PNEUMOVAS -pneumococcal vaccination in AAV treated with RTX Double dose of PCV13 at day 0 and day 7 followed by single dose of PPV23 at month 5 significantly improves antibody responses (2 in figure) @RheumNow #ACR22 Abstr#L016 https://t.co/qKqgvv7ZwI https://t.co/UHCuZNSF54
Richard Conway RichardPAConway
3 years 1 month ago
I see that despite the condensing of the #ACR22 to 3 days, people are keeping the tradition of leaving at the start of the last day despite it now being a full day. Personally don't think the 3 day meeting has worked, its too packed. @RheumNow
Patricia Harkins DrTrishHarkins
3 years 1 month ago
Promises to be a fantastic session!
🌟Delighted PMR is getting the attention it deserves 🌟
2pm GMT/ 9am EST
#ACR22 @RheumNow
@SattuiSEMD @EBRheum @drceowen https://t.co/ShRTS1DLXO
Richard Conway RichardPAConway
3 years 1 month ago
Wu et al Phase 3 RCT of Telitacicept (targets BlyS and APRIL) in SLE. Primary endpoint met at week 52! SRI(4) 67% vs 33% or 83% vs 38% (P<0.001 for both) depending on how you want to slice it. @RheumNow #ACR22 Abstr#L07 https://t.co/nnKr4AU8Jk https://t.co/9BVF6OljFQ
Richard Conway RichardPAConway
3 years 1 month ago
Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on lab values other than increase in trigs. Guess this is why they don't have lab monitoring on label? @RheumNow #ACR22 Abstr#2132 https://t.co/ueIVKQc6jr https://t.co/u99QE71VQ5
Dr. Rachel Tate uptoTate
3 years 1 month ago
"Less steroid is more" in multiple diseases. Dr. J Kolfenbach #ACR22 @RheumNow
Richard Conway RichardPAConway
3 years 1 month ago
van Nieuwland et al. Comparison US/PET/MRI in GCA. Good specificity but relatively low sensitivity for all. PET best for extra-cranial. MRI/US best for isolated cranial. @RheumNow #ACR22 Abstr#1617 https://t.co/CI3TtxOQJL https://t.co/3pJeGo49Gj
Richard Conway RichardPAConway
3 years 1 month ago
Stamatis et al. MI in systemic vasculitis vs controls. Only difference - less likely to have pre-existing CVD. No significant difference in outcomes - but this may be due to underpowered - see Figures. @RheumNow #ACR22 Abstr#1615 https://t.co/bYtMr1jGXN https://t.co/QABW2GiVFl
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#1756 More data on safety of #COVID vaccine to cite when counselling patients with inflammatory arthritis (IA). Data from COVAX registry (over 7000 pts) showed rates of serious adverse event was low 0.3% vs 2.5% in those with non-IA RMD group
@RheumNow https://t.co/iucDK1GpU4
Richard Conway RichardPAConway
3 years 1 month ago
Quinlivan et al. GORD in SSc. Common - 94%. GORD treatment assoc improved survival HR 0.58. No assoc with ILD development/severity/progression but GORD treatment assoc improved survival in ILD HR 0.5. If PPI+H2 HR 0.33 . @RheumNow #ACR22 Abstr#2159 https://t.co/zk718ziFGJ https://t.co/WctfOr9qyf
Richard Conway RichardPAConway
3 years 1 month ago
Guimarães et al Portugese registry data suggests similar retention rates in change of MOA compared to 2nd TNFi following failure of 1st TNFi. @RheumNow #ACR22 Abstr#2149 https://t.co/Er2FKwYdRv https://t.co/uMPSfMkjfa
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#2068 Data from John Hopkins showed leading cause of deaths (1985-2019) in #lupus were #SLE & Cardiovascular (both 23%), then cancer & infection.SLE deaths common in younger. African-American died younger vs White. Need to improve with therapies we now have @RheumNow https://t.co/4tDhr1Eodm
Poster Hall